QIBA PET Myocardial Blood Flow (MBF) Biomarker Committee (BC)

Monday, March 13, 2023, at 9 am CT Call Summary

In attendance

Robert deKemp, PhD (co-chair) Jonathan B. Moody, PhD (Co-Chair) Ian S. Armstrong, MPhys, MSc, PhD Charles Hayden, BS, MSEE Nancy Obuchowski, PhD John O. Prior, MD, PhD **RSNA Staff** Julie Lisiecki

Moderator: Dr. Moody

The following topics were discussed:

• Overview of Profile draft

Discussion

- Reviewed comments from Dr. Armstrong and discussed flow reserve within subject coefficient of variation (wCV)
- sCV for rest and stress add in Quadrature
- Rest and stress flow can be correlated which can reduce the wCV for MFR lower than expected
 Rest and stress are independent variables, whereas MFR is a dependent variable
- wCV is being used to determine the precision on the measurement, a measure of change over time
 - This utilizes within subject variability, assuming that anything else is due to real change
- wCV for MFR was lower than the rest flow, though this seems counter-intuitive
- Include frame of reference time for measurements
- Convert counts to counts per second by dividing by the frame duration
- Determine what steps are needed to assess the quality of the dynamic series for the claim
 - Dynamic image quality assistance, quality of fit
 - Aim for minimal patient motion
- Provide guidance for a more standardized assessment procedure
 - o Ensure that the scan was started on time, so that the full rise, starting from baseline is captured
 - o Guidance needed for time-activity shape requirements (input function)
 - o Take LV myocardium segmentation into consideration
 - o Review pre kinetic modeling and post kinetic modeling to find a quantitative cut off point

New action items:

- Dr. deKemp to provide names and email addresses of new members to be added
- All Make a list of important QA steps for before and after fitting; to discuss on next call
 - o Think about image header, reconstruction, physician responsibilities, and analysis paradigm
- All Continue to review Profile draft and Checklist examples from other Profiles
- All Choose sections based on your expertise to make comments and edits
- Expertise is needed in determining the measurement requirements; input needed from MBF device developers and users (Profile Section 3: Activities and Actors)

Ongoing action items: (please strike if complete)

- Mr. Hayden to provide some comments in a marked-up version to Drs. Moody and deKemp
- Dr. Moody to draft publication based on Dr. Obuchowski's meta-analysis on MBF repeatability
- Dr. Moody to start drafting the Radiologist (Actor) checklist per the streamlined Profile template
- Dr. Moody to work on protocol design tables and share papers to shared drive
- Dr. deKemp to craft a bias table and review the linearity plot, looking at K¹ vs. flow values
- Dr. Moody to work on a DRO model; will look at QIBA work with DCE-MRI
- Review needed for 3.3 Product Validation, 3.4 Periodic QA, and 3.7 Pharmaceutical Administration
- Dynamic phantom scan protocol in Section 4 Assessment Procedures to be fine-tuned by Dr. Moody

Next Call: March 27, 2023, at 9 am CT (2nd and 4th Mondays) at 9 am CT

Parties interested in joining the QIBA LinkedIn page for QIBA updates should visit: <u>https://www.linkedin.com/company/rsna-qiba</u>

QIBA Process Committee Resources

- Process Committee Leaders: <u>Kevin O'Donnell, MASc</u> (Chair) | <u>Michael Boss, PhD</u> (Co-Chair) <u>mailto:mboss@acr.org</u>
- Wiki Resources: <u>Dashboard</u> | <u>Profiles</u> | <u>QIBA Profile template</u> | <u>How to Write a QIBA Profile</u> | <u>Claim Guidance</u> <u>Vetting requirements</u>
- Inventory of QIBA tools: <u>QIBA LinkedIn page</u> (please join / follow) | <u>QIBA News</u> | <u>QIBA Community</u>
- Other: <u>QIBA Webpage</u> | <u>QIBA Wiki</u> | <u>QIBA Biomarker Committees</u> | <u>QIBA Organization Chart</u> | <u>Dropbox</u>
- EndNote: To obtain access to the RSNA EndNote citations, please email: sstanfa@rsna.org.